Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs JPMorgan Ultra Short Income ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while JPMorgan Ultra Short Income ETF trades at $50.47. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals.
| BIO | JPST | |
|---|---|---|
Market Cap | $8.04B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $339.75 | $50.78 |
52-Week Low | $241.71 | $50.40 |
Enterprise Value | $7.85B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
JPST trades at $50.44, down 0.02% with a bearish technical signal from moving averages. The ETF focuses on high-quality, short-term bonds, offering monthly dividends and capital preservation. Recent news highlights strong institutional inflows and its role as a cash alternative in volatile markets. Technical indicators show neutral oscillators but overall bearish momentum, with support and resistance clustered around $50.
Outlook remains stable for income-focused investors seeking low duration risk, though rising Treasury yields pose a headwind. Key risks include interest rate sensitivity and credit spread changes. Institutional ownership trends indicate growing advisor interest, supporting its defensive profile in uncertain rate environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →
